News Archive

November 2019

• Ad-hoc Releases Nov 24, 2019

  Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

  Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…
• Press Release Nov 21, 2019

  Novartis launches Innovation Prize for Assistive Tech to encourage new technologies that address unmet needs of the multiple sclerosis community

  The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MS Applications are…
• Press Release Nov 17, 2019

  Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

  Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated…
• Ad-hoc Releases Nov 15, 2019

  New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease

  Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.…
• Press Release Nov 15, 2019

  Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)

  If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1]) CHMP…
• Press Release Nov 13, 2019

  Novartis announces new strategy to provide innovative medicines to more patients in sub-Saharan Africa

  The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally A…
• Press Release Nov 12, 2019

  Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment

  Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when…
• Press Release Nov 12, 2019

  New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis

  42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1] PREVENT is…
• Press Release Nov 11, 2019

  Novartis data show tropifexor (LJN452) significantly improves several key biomarkers of NASH in patients with moderate to severe fibrosis

  The FLIGHT- FXR phase IIb study showed tropifexor, a highly potent non-bile acid FXR agonist, produces robust and dose-dependent reductions in hepatic fat and alanine aminotransferase compared to…
• Press Release Nov 11, 2019

  Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market

  Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market Planned acquisition reinforces Sandoz…
• Press Release Nov 05, 2019

  Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)

  Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only…
• Ad-hoc Releases Nov 01, 2019

  Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis

  Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira®*[1] Statistically…